APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sustained-release Medicine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Sustained-release Medicine Market Analysis and Forecast 2026-2032

21 December 2025196 pages

Choose your research edition.

Industry ResearchSustained-release Medicine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Sustained-release Medicine Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Sustained-release Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sustained-release Medicine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Sustained-release Medicine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Sustained-release Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Sustained-release Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Sustained-release Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Sustained-release Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Sustained-release Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Sustained-release Medicine include Zhuhai Rundu Pharmaceutical, Endo Pharmaceuticals, Takeda, Shanghai Shyndec Pharmaceutical, Sanofi, Johnson & Johnson, Novartis, Pfizer and China Res Double-Crane, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Sustained-release Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Sustained-release Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Sustained-release Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Sustained-release Medicine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Sustained-release Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Sustained-release Medicine revenue, projected growth trends, production technology, application and end-user industry.

Sustained-release Medicine Segment by Company

Zhuhai Rundu Pharmaceutical

Endo Pharmaceuticals

Takeda

Shanghai Shyndec Pharmaceutical

Sanofi

Johnson & Johnson

Novartis

Pfizer

China Res Double-Crane

Bayer

AbbVie

AstraZeneca

Collegium Pharmaceutical, Inc

Sustained-release Medicine Segment by Type

Original Ground Medicine

Generic Medicine

Sustained-release Medicine Segment by Application

Hospital

Drugstore

Other

Sustained-release Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained-release Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sustained-release Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained-release Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Sustained-release Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Sustained-release Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sustained-release Medicine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Sustained-release Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Original Ground Medicine Major Player Table 3. Generic Medicine Major Player Table 4. Global Sustained-release Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Drugstore Major Player Table 7. Other Major Player Table 8. Sustained-release Medicine Industry Trends Table 9. Sustained-release Medicine Industry Drivers Table 10. Sustained-release Medicine Industry Opportunities and Challenges Table 11. Sustained-release Medicine Industry Restraints Table 12. Global Sustained-release Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Sustained-release Medicine Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Sustained-release Medicine Market Share by Region (2021-2026) Table 15. Global Sustained-release Medicine Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Sustained-release Medicine Market Share by Region (2027-2032) Table 17. Global Sustained-release Medicine Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Sustained-release Medicine Revenue Market Share by Players (2021-2026) Table 19. Global Sustained-release Medicine Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Sustained-release Medicine Key Players Headquarters & Area Served Table 21. Global Sustained-release Medicine Players, Product Type & Application Table 22. Global Sustained-release Medicine Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Sustained-release Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Sustained-release Medicine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Sustained-release Medicine Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Sustained-release Medicine Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Sustained-release Medicine Revenue Market Share by Type (2021-2026) Table 29. Global Sustained-release Medicine Revenue Market Share by Type (2027-2032) Table 30. Global Sustained-release Medicine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Sustained-release Medicine Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Sustained-release Medicine Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Sustained-release Medicine Revenue Market Share by Application (2021-2026) Table 34. Global Sustained-release Medicine Revenue Market Share by Application (2027-2032) Table 35. Zhuhai Rundu Pharmaceutical Company Information Table 36. Zhuhai Rundu Pharmaceutical Business Overview Table 37. Zhuhai Rundu Pharmaceutical Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Zhuhai Rundu Pharmaceutical Sustained-release Medicine Product Portfolio Table 39. Zhuhai Rundu Pharmaceutical Recent Development Table 40. Endo Pharmaceuticals Company Information Table 41. Endo Pharmaceuticals Business Overview Table 42. Endo Pharmaceuticals Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Endo Pharmaceuticals Sustained-release Medicine Product Portfolio Table 44. Endo Pharmaceuticals Recent Development Table 45. Takeda Company Information Table 46. Takeda Business Overview Table 47. Takeda Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Takeda Sustained-release Medicine Product Portfolio Table 49. Takeda Recent Development Table 50. Shanghai Shyndec Pharmaceutical Company Information Table 51. Shanghai Shyndec Pharmaceutical Business Overview Table 52. Shanghai Shyndec Pharmaceutical Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Shanghai Shyndec Pharmaceutical Sustained-release Medicine Product Portfolio Table 54. Shanghai Shyndec Pharmaceutical Recent Development Table 55. Sanofi Company Information Table 56. Sanofi Business Overview Table 57. Sanofi Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Sanofi Sustained-release Medicine Product Portfolio Table 59. Sanofi Recent Development Table 60. Johnson & Johnson Company Information Table 61. Johnson & Johnson Business Overview Table 62. Johnson & Johnson Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Johnson & Johnson Sustained-release Medicine Product Portfolio Table 64. Johnson & Johnson Recent Development Table 65. Novartis Company Information Table 66. Novartis Business Overview Table 67. Novartis Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Novartis Sustained-release Medicine Product Portfolio Table 69. Novartis Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Pfizer Sustained-release Medicine Product Portfolio Table 74. Pfizer Recent Development Table 75. China Res Double-Crane Company Information Table 76. China Res Double-Crane Business Overview Table 77. China Res Double-Crane Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. China Res Double-Crane Sustained-release Medicine Product Portfolio Table 79. China Res Double-Crane Recent Development Table 80. Bayer Company Information Table 81. Bayer Business Overview Table 82. Bayer Sustained-release Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Bayer Sustained-release Medicine Product Portfolio Table 84. Bayer Recent Development Table 85. AbbVie Company Information Table 86. AbbVie Business Overview Table 87. AbbVie Sustained-release Medicine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. AbbVie Sustained-release Medicine Product Portfolio Table 89. AbbVie Recent Development Table 90. AstraZeneca Company Information Table 91. AstraZeneca Business Overview Table 92. AstraZeneca Sustained-release Medicine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. AstraZeneca Sustained-release Medicine Product Portfolio Table 94. AstraZeneca Recent Development Table 95. Collegium Pharmaceutical, Inc Company Information Table 96. Collegium Pharmaceutical, Inc Business Overview Table 97. Collegium Pharmaceutical, Inc Sustained-release Medicine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Collegium Pharmaceutical, Inc Sustained-release Medicine Product Portfolio Table 99. Collegium Pharmaceutical, Inc Recent Development Table 100. North America Sustained-release Medicine Revenue by Type (2021-2026) & (US$ Million) Table 101. North America Sustained-release Medicine Revenue by Type (2027-2032) & (US$ Million) Table 102. North America Sustained-release Medicine Revenue by Application (2021-2026) & (US$ Million) Table 103. North America Sustained-release Medicine Revenue by Application (2027-2032) & (US$ Million) Table 104. North America Sustained-release Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. North America Sustained-release Medicine Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Sustained-release Medicine Revenue by Country (US$ Million) & (2027-2032) Table 107. Europe Sustained-release Medicine Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Sustained-release Medicine Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Sustained-release Medicine Revenue by Application (2021-2026) & (US$ Million) Table 110. Europe Sustained-release Medicine Revenue by Application (2027-2032) & (US$ Million) Table 111. Europe Sustained-release Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Europe Sustained-release Medicine Revenue by Country (2021-2026) & (US$ Million) Table 113. Europe Sustained-release Medicine Revenue by Country (US$ Million) & (2027-2032) Table 114. China Sustained-release Medicine Revenue by Type (2021-2026) & (US$ Million) Table 115. China Sustained-release Medicine Revenue by Type (2027-2032) & (US$ Million) Table 116. China Sustained-release Medicine Revenue by Application (2021-2026) & (US$ Million) Table 117. China Sustained-release Medicine Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Sustained-release Medicine Revenue by Type (2021-2026) & (US$ Million) Table 119. Asia Sustained-release Medicine Revenue by Type (2027-2032) & (US$ Million) Table 120. Asia Sustained-release Medicine Revenue by Application (2021-2026) & (US$ Million) Table 121. Asia Sustained-release Medicine Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia Sustained-release Medicine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Asia Sustained-release Medicine Revenue by Region (US$ Million) & (2021-2026) Table 124. Asia Sustained-release Medicine Revenue by Region (US$ Million) & (2027-2032) Table 125. SAMEA Sustained-release Medicine Revenue by Type (2021-2026) & (US$ Million) Table 126. SAMEA Sustained-release Medicine Revenue by Type (2027-2032) & (US$ Million) Table 127. SAMEA Sustained-release Medicine Revenue by Application (2021-2026) & (US$ Million) Table 128. SAMEA Sustained-release Medicine Revenue by Application (2027-2032) & (US$ Million) Table 129. SAMEA Sustained-release Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. SAMEA Sustained-release Medicine Revenue by Country (2021-2026) & (US$ Million) Table 131. SAMEA Sustained-release Medicine Revenue by Country (US$ Million) & (2027-2032) Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Sustained-release Medicine Image Figure 2. Global Sustained-release Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sustained-release Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Original Ground Medicine Image Figure 5. Generic Medicine Image Figure 6. Global Sustained-release Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Sustained-release Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Drugstore Image Figure 10. Other Image Figure 11. Global Sustained-release Medicine Market Size (US$ Million) & (2021-2032) Figure 12. Global Sustained-release Medicine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Sustained-release Medicine Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Sustained-release Medicine Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Sustained-release Medicine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Sustained-release Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Sustained-release Medicine Revenue Market Share by Type (2021-2032) Figure 19. Global Sustained-release Medicine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Sustained-release Medicine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Sustained-release Medicine Revenue Market Share by Application (2021-2032) Figure 22. North America Sustained-release Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Sustained-release Medicine Revenue Share by Type (2021-2032) Figure 24. North America Sustained-release Medicine Revenue Share by Application (2021-2032) Figure 25. North America Sustained-release Medicine Revenue Share by Country (2021-2032) Figure 26. United States Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Sustained-release Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Sustained-release Medicine Revenue Share by Type (2021-2032) Figure 31. Europe Sustained-release Medicine Revenue Share by Application (2021-2032) Figure 32. Europe Sustained-release Medicine Revenue Share by Country (2021-2032) Figure 33. Germany Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Sustained-release Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Sustained-release Medicine Revenue Share by Type (2021-2032) Figure 43. China Sustained-release Medicine Revenue Share by Application (2021-2032) Figure 44. Asia Sustained-release Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Sustained-release Medicine Revenue Share by Type (2021-2032) Figure 46. Asia Sustained-release Medicine Revenue Share by Application (2021-2032) Figure 47. Asia Sustained-release Medicine Revenue Share by Region (2021-2032) Figure 48. Japan Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Sustained-release Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Sustained-release Medicine Revenue Share by Type (2021-2032) Figure 56. SAMEA Sustained-release Medicine Revenue Share by Application (2021-2032) Figure 57. SAMEA Sustained-release Medicine Revenue Share by Country (2021-2032) Figure 58. Brazil Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Sustained-release Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Original Ground Medicine
  • Generic Medicine
Applications
  • Hospital
  • Drugstore
  • Other
Companies covered
  • Zhuhai Rundu Pharmaceutical
  • Endo Pharmaceuticals
  • Takeda
  • Shanghai Shyndec Pharmaceutical
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • China Res Double-Crane
  • Bayer
  • AbbVie
  • AstraZeneca
  • Collegium Pharmaceutical, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Sustained-release Medicine Market by Type
  3. 1.2.1 Global Sustained-release Medicine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Original Ground Medicine
  5. 1.2.3 Generic Medicine
  6. 1.3 Sustained-release Medicine Market by Application
  7. 1.3.1 Global Sustained-release Medicine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Drugstore
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Sustained-release Medicine Market Dynamics
  1. 2.1 Sustained-release Medicine Industry Trends
  2. 2.2 Sustained-release Medicine Industry Drivers
  3. 2.3 Sustained-release Medicine Industry Opportunities and Challenges
  4. 2.4 Sustained-release Medicine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Sustained-release Medicine Market Perspective (2021-2032)
  2. 3.2 Global Sustained-release Medicine Growth Trends by Region
  3. 3.2.1 Global Sustained-release Medicine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Sustained-release Medicine Market Size by Region (2021-2026)
  5. 3.2.3 Global Sustained-release Medicine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Sustained-release Medicine Revenue by Players
  2. 4.1.1 Global Sustained-release Medicine Revenue by Players (2021-2026)
  3. 4.1.2 Global Sustained-release Medicine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Sustained-release Medicine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Sustained-release Medicine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Sustained-release Medicine Key Players Headquarters & Area Served
  7. 4.4 Global Sustained-release Medicine Players, Product Type & Application
  8. 4.5 Global Sustained-release Medicine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Sustained-release Medicine Market CR5 and HHI
  11. 4.6.3 2025 Sustained-release Medicine Tier 1, Tier 2, and Tier 3
5 Sustained-release Medicine Market Size by Type
  1. 5.1 Global Sustained-release Medicine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Sustained-release Medicine Revenue by Type (2021-2032)
  3. 5.3 Global Sustained-release Medicine Revenue Market Share by Type (2021-2032)
6 Sustained-release Medicine Market Size by Application
  1. 6.1 Global Sustained-release Medicine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Sustained-release Medicine Revenue by Application (2021-2032)
  3. 6.3 Global Sustained-release Medicine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Zhuhai Rundu Pharmaceutical
  2. 7.1.1 Zhuhai Rundu Pharmaceutical Company Information
  3. 7.1.2 Zhuhai Rundu Pharmaceutical Business Overview
  4. 7.1.3 Zhuhai Rundu Pharmaceutical Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Zhuhai Rundu Pharmaceutical Sustained-release Medicine Product Portfolio
  6. 7.1.5 Zhuhai Rundu Pharmaceutical Recent Developments
  7. 7.2 Endo Pharmaceuticals
  8. 7.2.1 Endo Pharmaceuticals Company Information
  9. 7.2.2 Endo Pharmaceuticals Business Overview
  10. 7.2.3 Endo Pharmaceuticals Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Endo Pharmaceuticals Sustained-release Medicine Product Portfolio
  12. 7.2.5 Endo Pharmaceuticals Recent Developments
  13. 7.3 Takeda
  14. 7.3.1 Takeda Company Information
  15. 7.3.2 Takeda Business Overview
  16. 7.3.3 Takeda Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Takeda Sustained-release Medicine Product Portfolio
  18. 7.3.5 Takeda Recent Developments
  19. 7.4 Shanghai Shyndec Pharmaceutical
  20. 7.4.1 Shanghai Shyndec Pharmaceutical Company Information
  21. 7.4.2 Shanghai Shyndec Pharmaceutical Business Overview
  22. 7.4.3 Shanghai Shyndec Pharmaceutical Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Shanghai Shyndec Pharmaceutical Sustained-release Medicine Product Portfolio
  24. 7.4.5 Shanghai Shyndec Pharmaceutical Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Sustained-release Medicine Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Johnson & Johnson
  32. 7.6.1 Johnson & Johnson Company Information
  33. 7.6.2 Johnson & Johnson Business Overview
  34. 7.6.3 Johnson & Johnson Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Johnson & Johnson Sustained-release Medicine Product Portfolio
  36. 7.6.5 Johnson & Johnson Recent Developments
  37. 7.7 Novartis
  38. 7.7.1 Novartis Company Information
  39. 7.7.2 Novartis Business Overview
  40. 7.7.3 Novartis Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Novartis Sustained-release Medicine Product Portfolio
  42. 7.7.5 Novartis Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Sustained-release Medicine Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 China Res Double-Crane
  50. 7.9.1 China Res Double-Crane Company Information
  51. 7.9.2 China Res Double-Crane Business Overview
  52. 7.9.3 China Res Double-Crane Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 China Res Double-Crane Sustained-release Medicine Product Portfolio
  54. 7.9.5 China Res Double-Crane Recent Developments
  55. 7.10 Bayer
  56. 7.10.1 Bayer Company Information
  57. 7.10.2 Bayer Business Overview
  58. 7.10.3 Bayer Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bayer Sustained-release Medicine Product Portfolio
  60. 7.10.5 Bayer Recent Developments
  61. 7.11 AbbVie
  62. 7.11.1 AbbVie Company Information
  63. 7.11.2 AbbVie Business Overview
  64. 7.11.3 AbbVie Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 AbbVie Sustained-release Medicine Product Portfolio
  66. 7.11.5 AbbVie Recent Developments
  67. 7.12 AstraZeneca
  68. 7.12.1 AstraZeneca Company Information
  69. 7.12.2 AstraZeneca Business Overview
  70. 7.12.3 AstraZeneca Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AstraZeneca Sustained-release Medicine Product Portfolio
  72. 7.12.5 AstraZeneca Recent Developments
  73. 7.13 Collegium Pharmaceutical, Inc
  74. 7.13.1 Collegium Pharmaceutical, Inc Company Information
  75. 7.13.2 Collegium Pharmaceutical, Inc Business Overview
  76. 7.13.3 Collegium Pharmaceutical, Inc Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Collegium Pharmaceutical, Inc Sustained-release Medicine Product Portfolio
  78. 7.13.5 Collegium Pharmaceutical, Inc Recent Developments
8 North America
  1. 8.1 North America Sustained-release Medicine Revenue (2021-2032)
  2. 8.2 North America Sustained-release Medicine Revenue by Type (2021-2032)
  3. 8.2.1 North America Sustained-release Medicine Revenue by Type (2021-2026)
  4. 8.2.2 North America Sustained-release Medicine Revenue by Type (2027-2032)
  5. 8.3 North America Sustained-release Medicine Revenue Share by Type (2021-2032)
  6. 8.4 North America Sustained-release Medicine Revenue by Application (2021-2032)
  7. 8.4.1 North America Sustained-release Medicine Revenue by Application (2021-2026)
  8. 8.4.2 North America Sustained-release Medicine Revenue by Application (2027-2032)
  9. 8.5 North America Sustained-release Medicine Revenue Share by Application (2021-2032)
  10. 8.6 North America Sustained-release Medicine Revenue by Country
  11. 8.6.1 North America Sustained-release Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Sustained-release Medicine Revenue by Country (2021-2026)
  13. 8.6.3 North America Sustained-release Medicine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Sustained-release Medicine Revenue (2021-2032)
  2. 9.2 Europe Sustained-release Medicine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Sustained-release Medicine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Sustained-release Medicine Revenue by Type (2027-2032)
  5. 9.3 Europe Sustained-release Medicine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Sustained-release Medicine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Sustained-release Medicine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Sustained-release Medicine Revenue by Application (2027-2032)
  9. 9.5 Europe Sustained-release Medicine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Sustained-release Medicine Revenue by Country
  11. 9.6.1 Europe Sustained-release Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Sustained-release Medicine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Sustained-release Medicine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Sustained-release Medicine Revenue (2021-2032)
  2. 10.2 China Sustained-release Medicine Revenue by Type (2021-2032)
  3. 10.2.1 China Sustained-release Medicine Revenue by Type (2021-2026)
  4. 10.2.2 China Sustained-release Medicine Revenue by Type (2027-2032)
  5. 10.3 China Sustained-release Medicine Revenue Share by Type (2021-2032)
  6. 10.4 China Sustained-release Medicine Revenue by Application (2021-2032)
  7. 10.4.1 China Sustained-release Medicine Revenue by Application (2021-2026)
  8. 10.4.2 China Sustained-release Medicine Revenue by Application (2027-2032)
  9. 10.5 China Sustained-release Medicine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Sustained-release Medicine Revenue (2021-2032)
  2. 11.2 Asia Sustained-release Medicine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Sustained-release Medicine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Sustained-release Medicine Revenue by Type (2027-2032)
  5. 11.3 Asia Sustained-release Medicine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Sustained-release Medicine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Sustained-release Medicine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Sustained-release Medicine Revenue by Application (2027-2032)
  9. 11.5 Asia Sustained-release Medicine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Sustained-release Medicine Revenue by Country
  11. 11.6.1 Asia Sustained-release Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Sustained-release Medicine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Sustained-release Medicine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Sustained-release Medicine Revenue (2021-2032)
  2. 12.2 SAMEA Sustained-release Medicine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Sustained-release Medicine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Sustained-release Medicine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Sustained-release Medicine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Sustained-release Medicine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Sustained-release Medicine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Sustained-release Medicine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Sustained-release Medicine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Sustained-release Medicine Revenue by Country
  11. 12.6.1 SAMEA Sustained-release Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Sustained-release Medicine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Sustained-release Medicine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst